mva-sars-2-s vaccinations

Vaccineexperimental

Clinical trial activity

4 trials · 10 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Oct 5, 2020 (NCT04569383)

Timeline

2020s

  1. Jan 1, 2020

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2021

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • SARS-CoV-2Immunity, active

    SARS-CoV-2 immunity, active

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05226390Phase 1Feb 24, 2022German Center for Infection Research, Gottfried Wilhelm Leibniz Universität Hannover, Hannover Medical School, IDT Biologika, University of Hamburg
NCT04895449Phase 1Jul 16, 2021CTC Bio, Inc., German Center for Infection Research, IDT Biologika, Ludwig Maximilians University, Philipps University of Marburg, University of Hamburg
NCT05950776Phase 2Jan 15, 2021Clinical Trial Center North, German Center for Infection Research, Ludwig Maximilians University, Philipps University of Marburg, University of Hamburg, University of Tuebingen
NCT04569383Phase 1Oct 5, 2020German Center for Infection Research, Ludwig Maximilians University, Philipps University of Marburg, University of Hamburg
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (10)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
German Center for Infection ResearchAcademic/Hospital4022020
University of HamburgAcademic/Hospital4322020
Ludwig Maximilians UniversityAcademic/Hospital3022020
Philipps University of MarburgAcademic/Hospital3022020
IDT BiologikaFor profit2012021
Clinical Trial Center NorthFor profit1012021
CTC Bio, Inc.For profit1012021
Gottfried Wilhelm Leibniz Universität HannoverAcademic/Hospital1112022
Hannover Medical SchoolAcademic/Hospital1012022
University of TuebingenAcademic/Hospital1012021
10 organizations
Page 1 / 1